Abrogation of Suppressor Cells Activity by cis-Diamminedichloroplatinum (CDDP) Treatment Using Therapeutic Doses in Ovarian Cancer Patients

Abrogation of Suppressor Cells Activity by cis-Diamminedichloroplatinum (CDDP) Treatment Using Therapeutic Doses in Ovarian Cancer Patients

We examined the activity of natural killer (NK) cells and suppressor cells and the population of peripheral blood lymphocytes before and after cis -diamminedichloroplatinum (CDDP) treatment using therapeutic doses in 15 ovarian cancer patients. CDDP did not decrease NK cell activity but selectively...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology 1994-02, Vol.52 (2), p.218-221
Hauptverfasser: Tsuda, Hiroshi, Kitahashi, Shigeru, Umesaki, Naohiko, Kanaoka, Yasushi, Kawabata, Masami, Ogita, Sachio
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Cisplatin - therapeutic use
Female
Humans
Killer Cells, Natural - drug effects
Killer Cells, Natural - physiology
Leukocyte Count - drug effects
Lymphocytes - drug effects
Lymphocytes - pathology
Medical sciences
Middle Aged
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - immunology
Ovarian Neoplasms - pathology
Pharmacology. Drug treatments
T-Lymphocytes, Regulatory - drug effects
T-Lymphocytes, Regulatory - physiology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We examined the activity of natural killer (NK) cells and suppressor cells and the population of peripheral blood lymphocytes before and after cis -diamminedichloroplatinum (CDDP) treatment using therapeutic doses in 15 ovarian cancer patients. CDDP did not decrease NK cell activity but selectively abrogated suppressor cell activity up to 7 days after treatment (P < 0.05). The CD56+CD16+ cell and CD8+CD11+ T cell populations significantly decreased; however, the CD4+2H4+ T cells, showed a significant increase after treatment (P < 0.05). We conclude that CDDP treatment using therapeutic doses could selectively abrogate suppressor cell activity.
ISSN:0090-8258
1095-6859
DOI:10.1006/gyno.1994.1034